Summary Between 1978 and 1983, 44 
Approximately 70% of patients with testicular seminoma present without clinical evidence of metastases (Stage I) and in the majority of the remainder metastases appear confined to infradiaphragnatic nodes (Stage II) (Peckham, 1981) . The early stage presentation together with the radiosensitivity of seminoma has resulted in excellent survival figures (Maier et al., 1968; Smithers et al., 1971; Castro & Gonzales, 1971; Doornbos et al., 1975; Kademian et al., 1976; Van der werf Messing, 1976; Calman et al., 1979; Thomas et al., 1982) . However, despite these good overall results, subgroups can be identified where the results of radiotherapy are less satisfactory. These include patients with bulky Stage II disease and Stage III and IV presentations (Ball et al., 1982) .
Experience in recent years has shown that seminomas are responsive to the chemotherapy used to treat non-seminomatous germ-cell tumours, suggesting that chemotherapy could be considered as an alternative to or in conjunction with radiotherapy in selected patients (Einhorn & Williams, 1980; Ball et al., 1982; Morse et al., 1983; Simon et al., 1983; Van Oosterom et al., 1984) .
Patients and methods

Patients
Between October 1978 and November 1983, 44 patients aged from 23 to 56 years were treated with chemotherapy containing cis-platinum (39 patients) Correspondence: M.J. Peckham. Received 28 November 1984; and in revised form 5 March 1985. or the platinum analogue cis-diammine-1, 1-cyclobutane dicarboxylate platinum II (CBDCA or JM8) as a single agent (5 patients). No patient had received prior chemotherapy, but 13 had been irradiated and subsequently relapsed. Of the total group, 36 patients had primary intra-scrotal testicular seminomas and 1 patient had a massive seminoma in an undescended abdominal testis. Four patients (all male) had primary mediastinal seminomas, in two with lung infiltration and in one with involvement of a vertebra and extradural cord compression. Three patients had no detectable primary tumour but on the basis of the pattern of spread were presumed to have occult seminomas in the testis.
The observation time from start of chemotherapy for the series is 12 to 73 months, median 36 months.
Staging
This included chest X-ray, lymphography, CT scans of chest and abdomen, i.v. urography and in selected patients Gallium 67 scanning. Serum concentrations of alphafoetoprotein (AFP) and human chorionic gonadotrophin (HCG) were measured initially in all patients and employed as a monitor of disease progress thereafter.
The Royal Marsden staging classification Chemotherapy in the initial period of the study consisted of cis-platinum, vinblastine and bleomycin (PVB) (Einhorn & Donohue, 1977) . Subsequently, bleomycin, etoposide and cis-platinum (BEP) (Peckham et al., 1983) were employed. Etoposide and cis-platinum were employed in 1 patient. JM8 was employed in 5 patients as a single agent in a dose of 400mgm-2 given as a 30min i.v. infusion every 3-4 weeks (Calvert et al., 1982) . Four patients had 4 doses and one had 6. A sixth patient received 4 injections of JM8 for a mediastinal seminoma with lung infiltration followed by 2 cycles of BEP, since despite an excellent response, residual thickening was present. Of the 44 patients, 31 (70%) received 4 cycles of chemotherapy, two had 2 cycles, three 5 cycles, seven 6 cycles and one 8 cycles. The number of patients receiving each type of chemotherapy is shown in Table I .
Between 1978 and 1982 all but 7 patients had involved site irradiation after chemotherapy. The 7 were identified these were monitored carefully at subsequent follow-up visits. AFP and HCG serum levels were measured at each visit in all patients.
Results
Of the 44 patients, 40 (90%) are alive and 4 have died of germ-cell malignancy, 2 with nonseminomatous metastases. Of those who are alive, 39 have remained continuously disease free for 12-73 months (median 36 months) since treatment and one is disease free 17 months after relapse following initial chemotherapy.
Results by type of chemotherapy As shown in Table I the results obtained with the different approaches used are comparable.
Influence of prior radiotherapy Of 13 patients who had been previously irradiated 3 (23%) have died compared with 1/31 (3%) previously untreated patients (Table II) . The results Influence of post-chemotherapy radiotherapy (Table IV) Of 15 previously untreated patients receiving involved site radiotherapy after chemotherapy, one relapsed. Similarly there was only one relapse in 16 patients treated with chemotherapy alone. Although follow-up times are shorter in the latter group (median 19 months compared with 43 months), it is unlikely that any significant differences will emerge between these two approaches. chemotherapy HCG levels were low in all 5 relapsing patients (Table VI) suggesting that this is not a significant prognostic factor at least when combination chemotherapy is employed.
Toxicity
There were no deaths attributable to the effects of chemotherapy. The toxicity of PVB, BEP and EP has been described elsewhere (Einhorn and Donohue, 1977; Peckham et al., 1983; Peckham & Horwich, 1985) . Of the 5 patients treated with JM8, 2 experienced nausea and vomiting with each injection, 2 experienced some nausea but did not vomit and one was asymptomatic for two injections and experienced nausea and vomiting with two. Hair loss did not occur and there was no impairment of renal function or peripheral neuropathy. Nadir blood counts were as follows: White count, 2-3.9 x i0 ml-1; platelets, 37-62 x 103 ml-' and haemoglobin, 9.3-13.4 G I l. The gaps between injections of JM8 were as follows: <21 days, 6 gaps; 22-28 days, 7 gaps; 29-35 days, 2 gaps with one interval of 36 days and one of 39 days.
Discussion
The present results together with those reported from other centres show that seminoma is highly sensitive to platinum-containing chemotherapy (Table VIII) . More limited data indicate that platinum analogues are active as single-agents. As shown in Table IX Samuels et al. (1983) have aCollected data from Indiana, Netherlands and Madrid. bIncludes surgical and clinical assessment, using clinical criteria only 9/22 (40%) achieved CR. bOne patient received radiotherapy after JM8.
reported 32 patients treated with cis-platinum ±cyclophosphamide of whom 30 are in continuing complete remission, 27 for more than 18 months. In their study cis-platinum was given weekly but it is not clear how many patients also had cyclophosphamide. Oliver (1984) has reported on 14 patients treated with cis-platinum alone of whom 10 are disease free. Of 10 untreated patients 9 are disease free. So far as the use of combination chemotherapy is concerned, the apparent effectiveness of platinum analogues as single agents raises doubts about the contribution of other drugs included in the regimens summarized in Table VIII . Samuels et al. (1983) have reported on 18 patients treated with bleomycin, cyclophosphamide, vincristine, methotrexate and 5 fluorouracil of whom 10 achieved CR but five subsequently failed. All 7 patients treated with vinblastine and bleomycin failed to achieve CR and died. Since the latter combination resulted in CR rates of -50% in patients with nonseminomatous germ-cell tumours, it appears that the spectrum of drugs active in seminoma and nonseminoma may differ substantially. A major difference between the present series and those previously reported is the complete response (CR) rate of 32% which is considerably lower than the figure obtained at other centres. This difference is likely to reflect differences in the time at which response was assessed as well as the methods of assessment. It is clear that other centres have also observed residual masses after chemotherapy. Thus in the memorial series of 22 patients, only 9 (40%) achieved complete disappearance of masses and 10 were submitted to surgery for residual abnormalities (Morse et al., 1983) . All 10 patients were histologically negative. Of the 10 patients reported by Simon et al. (1983) seven were explored after chemotherapy and all were histologically negative.
It is clear that residual masses are common after completion of chemotherapy for advanced seminoma, particularly if disease is bulky initially. These masses resolve slowly over months, and in some instances, years. Surgical exploration is complicated by the densely adherent fibrotic nature of the residuum and generally proves negative. In addition to the 17 patients undergoing laparotomy as described above four patients in the present series were explored and all were negative. Surgery is therefore not advocated, although careful monitoring of residual masses is essential. In this context preliminary data indicate that placental alkaline phosphatase is likely to prove a useful marker in seminoma (Lange et al., 1982) .
Recurrences can occur in patients achieving complete remission and those who are histologically negative at surgery. As shown in Table VIII 1/19 CR patients in the series of Morse et al. (1983) relapsed as did 3/10 patients reported by Simon et al. (1983) . In the latter group 3/7 patients, who were histologically negative at surgery relapsed as did 1/4 in the present series. None of 10 surgically negative patients reported by Morse relapsed.
Although the role of adjuvant radiotherapy after chemotherapy has not been formally investigated in a randomized trial, limited data summarized in Table IV suggest that it is unnecessary. Gradual resolution of residual masses occurs and as noted above the histology of resected tissue has generally proved negative.
To date there is scanty information on time to relapse after combination chemotherapy for advanced seminoma. Relapses in the present series occurred at 1, 3, 5, 15 and 26 months after chemotherapy and in the series of Simon et al. (1983) at 6, 7 and 8 months. Hence 6/8 relapses have been within the first year of chemotherapy.
In conclusion, seminoma is a highly chemoresponsive tumour in which the influence of tumour volume on the outcome of chemotherapy appears to be less obvious than is the case for non-seminomas although residual masses are commonly present one month after completion of chemotherapy. The results of surgery show that such masses are almost invariably negative histologically and often densely fibrotic. Spontaneous resolution of residual masses occurs, often over a period of months or years. There is no evidence that post-chemotherapy radiotherapy is contributory.
